| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
2,331 |
1,519 |
$163K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
426 |
338 |
$42K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
596 |
452 |
$23K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
221 |
195 |
$20K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
696 |
504 |
$19K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
211 |
193 |
$17K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
828 |
588 |
$11K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
74 |
64 |
$6K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
125 |
106 |
$4K |
| 90461 |
|
61 |
56 |
$1K |
| 99383 |
|
13 |
12 |
$993.60 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
13 |
13 |
$690.17 |
| 87807 |
|
47 |
38 |
$530.02 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
14 |
14 |
$168.68 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
14 |
14 |
$0.73 |